Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: A patient perspective

Patient Preference and Adherence

Volumn 9, Issue , 2015, Pages 121-131

  Bolge, Susan C ^a   Goren, Amir ^b   Tandon, Neeta ^a  

^a Janssen Scientific Affairs LLC   (United States)

^b KANTAR HEALTH   (United States)

Author keywords

Anti TNF; Persistence; References; Subcutaneous injection

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE BURNING; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT ATTITUDE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SKIN REDNESS; TREATMENT WITHDRAWAL; VERY ELDERLY;

EID: 84921799551     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S70834     Document Type: Article

References (27)

1. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5): 907–927.
2. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581.
3. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 Suppl 1):1–12.
4. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009;7:25.
5. David G, Tandon N, Waters HC, Gunnarsson C, Kavanaugh A. Rheumatoid arthritis and total hip and knee replacement: impact of biologics. Am J Pharm Benefits. In press 2014.
6. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S35–S61.
7. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–639.
8. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011;13 Suppl 1:S5.
9. Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther. 2011;13 Suppl 1:S3.
10. De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323.
11. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740.
12. Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36(10):2171–2177.
13. Ingham M, Reed G, Bolce R, et al. Patterns of anti-TNF treatment in the CORRONA registry: observed responses to maintenance, switching and discontinuation [abstract]. Ann Rheum Dis. 2011;70(Suppl 3):415.
14. Markenson JA, Gibofsky A, Palmer WR, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol. 2011;38(7): 1273–1281.
15. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 2008;59(10): 1519–1526.
16. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62(6):857–864.
17. Curtis JR, Hobar C, Hansbrough K. Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. Curr Med Res Opin. 2011;27:71–78.
18. da Silva JA, Ramiro S, Pedro S, Rodrigues A, Vasconcelos JC, Benito-Garcia E. Patients- and physicians-priorities for improvement. The case of rheumatic diseases. Acta Reumatol Port. 2010;35(2):192–199.
19. Enbrel® (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation; 2013.
20. Humira® (adalimumab) [package insert]. North Chicago, IL: AbbVie, Inc.; 2014.
21. Cimzia® (certolizumab) [package insert]. Smyrna, GA: UCB, Inc.; 2013.
22. Simponi® (golimumab) [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2014.
23. Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther. 2004;6 Suppl 2:S12–S18.
24. Fraenkel L, Bogardus S, Concato J, Felson D. Risk communication in rheumatoid arthritis. J Rheumatol. 2003;30(3):443–448.
25. van den Bemt BJ, van Lankveld WG. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheumatol. 2007;3(12):681.
26. Beck M. Searching for Side Effects [webpage on the Internet]. New York, NY: The Wall Street Journal; 2012. Available from: http://online.wsj.com/article/SB10001424052970203920204577193052426275904.html?KEYWORDS=Searching+for+Side+Effects. Accessed February 6, 2013.
27. Tanaka Y, Hirata S. Is it possible to withdraw biologics from therapy in rheumatoid arthritis? Clin Ther. 2013;35(12):2028–2035.